Skip to main content

Iron-Deficiency Anemia

Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
NCT01101399 | PHASE 3 | INTERVENTIONAL

Anaemia and functional iron deficiency are common conditions in patients with lymphoid malignancies, conditions which reduce significantly the quality of life and increase morbidity and mortality. Traditionally, Erythropoiesis Stimulating Agents (ESAs) have been used, but recently their use has been shown to have a negative impact on overall survival in different oncology populations. Recently published data suggest that intravenous (IV) iron can be effective in anaemia treatment, even without ESAs. This exploratory study is the first clinical project with ferric carboxymaltose (FCM) in patients with lymphoid malignancies: the data generated may be used for further evaluations of the drug in larger populations. In this study, 1,000 mg of IV iron as FCM will be administered on the same day or within 24 hours before or after chemotherapy treatment. The primary objective is to evaluate the efficacy of FCM in the correction of haemoglobin levels in anaemic subjects with lymphoid malignanci

Trial Information
2 Sites
19 Participants
Recruiting
18 Years to 50 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Universittsklinikum HamburgEppendorf
Hamburg,Germany,20246
Department of Medicine, St Grans Hospital (Capio St Grans Sjukhus)
Stockholm,Sweden,SE-11281

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov